ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last4,421 to 4,440 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Distress Screening vs No Screening: deaths from any cause25 of 744

16 of 692

1.0 points

-0.7 to 2.8

1,436NCT02941614

Implementing Systematic Distress Screening in Breast Cancer

Continuous Hormonal Therapy vs Intermittent Hormonal Therapy: serious adverse events19 of 732

10 of 702

1.2 points

-0.3 to 2.7

1,434NCT00002651

SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer

Donepezil SR 23 mg vs Donepezil IR 10 mg: serious adverse events80 of 963

45 of 471

-1.2 points

-4.6 to 1.8

1,434NCT00478205

Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease

Remote Ischemic Conditioning (RIC) vs Sham: deaths from any cause41 of 713

47 of 720

-0.8 points

-3.3 to 1.7

1,433NCT03481777

Remote Ischemic Conditioning in Patients With Acute Stroke (RESIST)

Remote Ischemic Conditioning (RIC) vs Sham: serious adverse events335 of 713

325 of 720

1.8 points

-3.3 to 7.0

1,433NCT03481777

Remote Ischemic Conditioning in Patients With Acute Stroke (RESIST)

Arm D - Ivermectin 600 vs Arm D - Placebo: deaths from any cause1 of 708

0 of 724

0.1 points

-0.4 to 0.8

1,432NCT05894538

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm D (Ivermectin 600)

Arm D - Ivermectin 600 vs Arm D - Placebo: serious adverse events6 of 708

4 of 724

0.3 points

-0.7 to 1.3

1,432NCT05894538

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm D (Ivermectin 600)

Short Storage vs Standard Issue: deaths from any cause49 of 716

45 of 714

0.5 points

-2.1 to 3.1

1,430NCT01977547

Age of Blood in Children in Pediatric Intensive Care Units

Short Storage vs Standard Issue: Mortality49 of 716

45 of 714

0.5 points

-2.1 to 3.1

1,430NCT01977547

Age of Blood in Children in Pediatric Intensive Care Units

Arm D - Ivermectin 600 vs Arm D - Placebo: Number of Participants With Mortality1 of 708

0 of 722

0.1 points

-0.4 to 0.8

1,430NCT05894538

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm D (Ivermectin 600)

Arm D - Ivermectin 600 vs Arm D - Placebo: Number of Participants With Hospitalization or Death7 of 708

2 of 722

0.7 points

-0.2 to 1.8

1,430NCT05894538

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm D (Ivermectin 600)

Arm D - Ivermectin 600 vs Arm D - Placebo: Number of Participants With Hospitalization, Urgent Care, Emergency Room Visit, or Death39 of 708

42 of 722

-0.3 points

-2.7 to 2.1

1,430NCT05894538

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm D (Ivermectin 600)

Tiotropium Treatment - MAT1 vs Glycopyrronium Treatment - MAT2: deaths from any cause52 of 665

67 of 765

-0.9 points

-3.8 to 2.0

1,430NCT06053541

Morbid Rates After Spiriva Chronic Obstructive Pulmonary Disease (COPD) Protocol Change

Edoxaban vs Vitamin K Antagonist (VKA): Number of Participants Who Experienced Major Bleeding (Adjudicated Data) Based on ISTH Criteria in Participants Taking Edoxaban vs VKA98 of 713

68 of 713

4.2 points

0.9 to 7.6

1,426NCT02943785

Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF)

Edoxaban vs Vitamin K Antagonist (VKA): Number of Participants Who Experienced Myocardial Infarctions (MI) in Participants Taking Edoxaban vs VKA (Adjudicated Data)12 of 713

7 of 713

0.7 points

-0.6 to 2.0

1,426NCT02943785

Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF)

Edoxaban vs Vitamin K Antagonist (VKA): Number of Participants Who Experienced Major Adverse Cardiac Events (MACE) in Participants Taking Edoxaban vs VKA (Adjudicated Data)61 of 713

53 of 713

1.1 points

-1.7 to 4.0

1,426NCT02943785

Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF)

Edoxaban vs Vitamin K Antagonist (VKA): Number of Participants Who Experienced Major Adverse Cardiac and Cerebrovascular Events (MACCE) in Participants Taking Edoxaban vs VKA (Adjudicated Data)86 of 713

80 of 713

0.8 points

-2.5 to 4.2

1,426NCT02943785

Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF)

Edoxaban vs Vitamin K Antagonist (VKA): Number of Participants Who Experienced Systemic Embolic Events in Participants Taking Edoxaban vs VKA (Adjudicated Data)2 of 713

3 of 713

-0.1 points

-1.0 to 0.6

1,426NCT02943785

Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF)

Edoxaban vs Vitamin K Antagonist (VKA): Number of Participants Who Experienced Net Adverse Clinical Events (Adjudicated Data) Based on ISTH Criteria in Participants Taking Edoxaban vs VKA170 of 713

157 of 713

1.8 points

-2.5 to 6.2

1,426NCT02943785

Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF)

Edoxaban vs Vitamin K Antagonist (VKA): Number of Participants Who Experienced a Composite of Adverse Events in Participants Taking Edoxaban vs VKA (Adjudicated Data)151 of 713

123 of 713

3.9 points

-0.2 to 8.0

1,426NCT02943785

Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF)

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=222"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=222

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT02941614-deaths",
        "title": "Distress Screening vs No Screening: deaths from any cause",
        "summary": "25 of 744 against 16 of 692; risk difference 1.0 points, 95% interval -0.7 to 2.8; NCT02941614, Implementing Systematic Distress Screening in Breast Cancer",
        "record": "/library/comparisons/NCT02941614-deaths",
        "nct_id": "NCT02941614",
        "kind": "deaths",
        "participants": 1436,
        "risk_difference": {
          "value": 0.010480763254397413,
          "lower": -0.007247930307557975,
          "upper": 0.028351718038538774
        },
        "group_1": "25 of 744",
        "group_2": "16 of 692",
        "difference": "1.0 points",
        "interval": "-0.7 to 2.8",
        "trial_title": "Implementing Systematic Distress Screening in Breast Cancer"
      },
      {
        "id": "NCT00002651-sae",
        "title": "Continuous Hormonal Therapy vs Intermittent Hormonal Therapy: serious adverse events",
        "summary": "19 of 732 against 10 of 702; risk difference 1.2 points, 95% interval -0.3 to 2.7; NCT00002651, SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer",
        "record": "/library/comparisons/NCT00002651-sae",
        "nct_id": "NCT00002651",
        "kind": "serious-adverse-events",
        "participants": 1434,
        "risk_difference": {
          "value": 0.01171126990799122,
          "lower": -0.003280687947063798,
          "upper": 0.02734822646874087
        },
        "group_1": "19 of 732",
        "group_2": "10 of 702",
        "difference": "1.2 points",
        "interval": "-0.3 to 2.7",
        "trial_title": "SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=223",
  "request_id": "5NZJ69J8BphlLTyk"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

Instruments

The conductscience.com catalog

One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.

Drugs and targets

Open Targets

One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.

Diseases

Open Targets

One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.

Companies

ClinicalTrials.gov

One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.

Cell lines

Cellosaurus

One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.

Journal index

PubMed and NLM's journal list

One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?